Comments
Loading...

Larimar Therapeutics

LRMRNASDAQ
Logo brought to you by Benzinga Data
$3.58
0.123.47%
Pre-Market: Feb 7, 6:45 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$26.00
Lowest Price Target1
$14.00
Consensus Price Target1
$18.90

Larimar Therapeutics (NASDAQ:LRMR) Stock, Analyst Ratings, Price Targets, Forecasts

Quote.Descriptions.analyst-ratings.

Analyst Trends and Forecast
2
Sep 24
4
Oct 24
1
Nov 24
2
Dec 24
2
Jan
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.4
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Truist Securities
HC Wainwright & Co.
Oppenheimer
Wedbush
Jones Trading

1calculated from analyst ratings

Analyst Ratings for Larimar Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Larimar Therapeutics (LRMR) stock?

A

The latest price target for Larimar Therapeutics (NASDAQ:LRMR) was reported by Truist Securities on January 29, 2025. The analyst firm set a price target for $18.00 expecting LRMR to rise to within 12 months (a possible 402.79% upside). 19 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Larimar Therapeutics (LRMR)?

A

The latest analyst rating for Larimar Therapeutics (NASDAQ:LRMR) was provided by Truist Securities, and Larimar Therapeutics initiated their buy rating.

Q

When was the last upgrade for Larimar Therapeutics (LRMR)?

A

The last upgrade for Larimar Therapeutics Inc happened on November 17, 2023 when Citigroup raised their price target to $4.5. Citigroup previously had a neutral for Larimar Therapeutics Inc.

Q

When was the last downgrade for Larimar Therapeutics (LRMR)?

A

The last downgrade for Larimar Therapeutics Inc happened on February 15, 2022 when William Blair changed their price target from N/A to N/A for Larimar Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Larimar Therapeutics (LRMR)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Larimar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Larimar Therapeutics was filed on January 29, 2025 so you should expect the next rating to be made available sometime around January 29, 2026.

Q

Is the Analyst Rating Larimar Therapeutics (LRMR) correct?

A

While ratings are subjective and will change, the latest Larimar Therapeutics (LRMR) rating was a initiated with a price target of $0.00 to $18.00. The current price Larimar Therapeutics (LRMR) is trading at is $3.58, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch